TrpV1 receptor activation rescues neuronal function and network gamma oscillations from Aβ-induced impairment in mouse hippocampus in vitro.
Hugo Balleza-TapiaSophie CruxYuniesky Andrade-TalaveraPablo Dolz-GaitonDaniela PapadiaGefei ChenJan JohanssonAndré FisahnPublished in: eLife (2018)
Amyloid-β peptide (Aβ) forms plaques in Alzheimer's disease (AD) and is responsible for early cognitive deficits in AD patients. Advancing cognitive decline is accompanied by progressive impairment of cognition-relevant EEG patterns such as gamma oscillations. The endocannabinoid anandamide, a TrpV1-receptor agonist, reverses hippocampal damage and memory impairment in rodents and protects neurons from Aβ-induced cytotoxic effects. Here, we investigate a restorative role of TrpV1-receptor activation against Aβ-induced degradation of hippocampal neuron function and gamma oscillations. We found that the TrpV1-receptor agonist capsaicin rescues Aβ-induced degradation of hippocampal gamma oscillations by reversing both the desynchronization of AP firing in CA3 pyramidal cells and the shift in excitatory/inhibitory current balance. This rescue effect is TrpV1-receptor-dependent since it was absent in TrpV1 knockout mice or in the presence of the TrpV1-receptor antagonist capsazepine. Our findings provide novel insight into the network mechanisms underlying cognitive decline in AD and suggest TrpV1 activation as a novel therapeutic target.
Keyphrases
- cognitive decline
- mild cognitive impairment
- neuropathic pain
- working memory
- high glucose
- diabetic rats
- drug induced
- multiple sclerosis
- end stage renal disease
- oxidative stress
- induced apoptosis
- chronic kidney disease
- newly diagnosed
- mouse model
- functional connectivity
- cell proliferation
- anti inflammatory
- patient reported outcomes
- brain injury
- subarachnoid hemorrhage